Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin
In enoxaparin-treated subjects, andexanet reduced anti-Xa activity and achieved effective hemostasis in 88% of patients. Results align with findings of patients using apixaban, rivaroxaban, or edoxaban.
Authors
- Michiel Coppens (ORCID: https://orcid.org/0000-0001-6891-9062)
- Genmin Lu (ORCID: https://orcid.org/0000-0002-1518-4434)
- Truman J. Milling (ORCID: https://orcid.org/0000-0002-5588-0426)
- Thijs F. van Haaps (ORCID: https://orcid.org/0000-0002-8358-2426)
- Alexander P. Benz (ORCID: https://orcid.org/0000-0003-2555-1266)
- Per Ladenvall (ORCID: https://orcid.org/0000-0002-0300-8070)
- John W. Eikelboom (ORCID: https://orcid.org/0000-0003-4126-1285)
- Lizhen Xu (ORCID: https://orcid.org/0000-0003-4921-7238)
- Mark Crowther (ORCID: https://orcid.org/0009-0004-6072-7735)
- Saskia Middeldorp
- Lisa Holer
- Stephan Nolan
Institutions
- Radboud University Nijmegen (NL)
- Johannes Gutenberg University Mainz (DE)
- Seton Medical Center (US)
- Population Health Research Institute (CA)
- Radboud University Medical Center (NL)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- AstraZeneca (Australia) (AU)
- AstraZeneca (Sweden) (SE)
- Amsterdam University Medical Centers (NL)
- Alexion Pharma (Switzerland) (CH)
- McMaster University (CA)
Publication Details
- Journal
- Research and Practice in Thrombosis and Haemostasis
- Published
- 2025-09-24
- DOI
- https://doi.org/10.1016/j.rpth.2025.103191
- Primary Topic
- Venous Thromboembolism Diagnosis and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Sanofi
- F. Hoffmann-La Roche
- CSL Behring
- Boston Scientific Corporation
- Norgine